Farnesyl transferase inhibitors in clinical development

By Caponigro Francesco   Casale Marina   Bryce Jane  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 6, 2003-06 ,pp. : 943-954

Informa Healthcare

Access to resources Recommend Favorite

Farnesyl transferase inhibitors in the treatment of breast cancer

By Kelland Lloyd R  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 413-421

Informa Healthcare

Access to resources Recommend Favorite

Controlled Exploration of Structural Databases: The Case of Farnesyl Transferase Inhibitors

By  

Medicinal Chemistry, Vol. 5, Iss. 3, 2009-05 ,pp. : 208-215

Bentham Science Publishers

Access to resources Recommend Favorite

Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations

By  

Current Topics in Medicinal Chemistry, Vol. 3, Iss. 10, 2003-01 ,pp. : 1103-1114

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Design of Selective Cyclooxygenase-2 Inhibitors as Non-Ulcerogenic, Anti-Inflammatory Drugs with Potential Utility as Anti-Cancer Agents

By  

Current Drug Targets, Vol. 2, Iss. 1, 2001-03 ,pp. : 79-106

Bentham Science Publishers

Access to resources Recommend Favorite